INTRODUCTION
Primary congenital glaucoma [PCG (MIM 231300)] is an autosomal-recessive disorder of the eye, caused by developmental defects in the trabecular meshwork (TM) and anterior chamber angle (1, 2) . It has an onset in the neonatal or early infantile period. The developmental defects cause obstruction of aqueous outflow leading to raised intraocular pressure (IOP) that damages the optic nerve and if left untreated, leads to irreversible blindness (3, 4) . The disease prevalence is very high among the inbred populations [1 in 1250 among the Slovakian Gypsys (5), 1 in 2500 among the Saudi Arabians (6) and 1 in 3300 among the Indian population in Andhra Pradesh (7)] compared with the western (1 in 10 000 to 1 in 20 000) populations (3, 5) .
Three chromosomal loci, viz. GLC3A [2p22-p21 (MIM 231300)] (8), GLC3B [1p36.2-p36.1 (MIM %600975)] (9) and GLC3C [14q23 (10) ], have been identified by linkage analysis, and the human cytochrome P450 gene CYP1B1 (MIM 601771) on GLC3A has been widely implicated in PCG (11, 12) . Allelic heterogeneity of CYP1B1 is the hallmark of * To whom correspondence should be addressed at: Kallam Anji Reddy Molecular Genetics Laboratory, Champalimaud Translational Centre, Brien Holden Eye Research Centre, L.V. Prasad Eye Institute, Road No. 2, Banjara Hills, Hyderabad 500034, India. Tel: +91 4030612524; Fax: +91 4023548271; Email: subho@lvpei.org or subho_c@yahoo.com PCG, and a wide spectrum of mutations has been observed in the coding region of CYP1B1 worldwide (13) . Globally, these mutations are clustered on specific intragenic haplotypes irrespective of their geographical locations that have provided evidence of strong founder effects (14, 15) . Rarely, CYP1B1 is associated in other primary glaucomas: both primary openangle glaucoma [POAG (MIM 137760)] (16) (17) (18) and primary angle closure glaucoma [PACG (19) ]. Interestingly, the mutation spectrum in the primary glaucomas was similar to that found in PCG and occurred on the same haplotype backgrounds (19) .
Other glaucoma-associated candidate genes such as MYOC [MIM 601652 (20, 21) ] and FOXC1 [MIM 601090 (22) ] have exhibited a limited involvement in PCG. Recently, null mutations in LTBP2 gene (MIM 602091) flanking the GLC3C locus has been characterized in a few PCG families (23) . However, the mutation spectrum of LTBP2 across diverse PCG populations is yet to be determined.
CYP1B1 is an estrogen-metabolizing enzyme of the CYP1 gene family (24, 25) . It forms metabolites via hydroxylation of CYP450 and catalyzes 4-hydroxylation of the 17b-estradiol (26) . It has a ubiquitous expression in multiple tissues that include heart, lung, liver, kidney and reproductive tissues (27) . Variants in the CYP1B1 protein coding region have exhibited enhanced activity and altered kinetics (28, 29) . Although the exact mechanism by which CYP1B1 causes glaucoma is yet unknown, Cyp1b1 2/2 mice have exhibited structural abnormalities in the ocular drainage structures similar to human PCG (30, 31) .
The coding region of CYP1B1 has been screened extensively in PCG patients, but relatively fewer studies have examined the promoter region (21, 32) . Because of the extensive involvement of CYP1B1 in PCG, the apparent lack of involvement of this gene in a substantial ( 50%) fraction of PCG patients (13, 14, (20) (21) (22) together with a large variability in post-treatment control of IOP in patients harboring CYP1B1 mutations prompted us to hypothesize that variations in other genomic regions, especially the CYP1B1 promoter, may be responsible for the disease.
RESULTS
The distribution of CYP1B1 mutations among the PCG, POAG and PACG cases are provided in Table 1 . Resequencing of the CYP1B1 promoter and the untranslated region revealed three variants, of which two were in the promoter and the other in the non-coding exon 1 (Fig. 1) . There was no significant deviation from Hardy -Weinberg equilibrium for these SNPs in the normal controls.
Among the observed variants, rs2567206 (T2805C) was significantly associated with PCG (P ¼ 6.01 × 10
24
), whereas the others were monomorphic (MAF , 0.05; Table 2 ). There was no association between the rs2567206 SNP with PCG cases that had either a heterozygous mutation (P ¼ 0.503) or did not harbor any CYP1B1 mutation (P ¼ 0.328). The genotype counts for the rs2567206 SNP in different categories of patients are provided in Supplementary Material, Table S1 .
Additionally, we also assayed rs2567206 in a cohort of POAG and PACG but no association was evident with these non-congenital glaucoma cases ( Table 3 ). As the number of primary glaucoma cases with a homozygous CYP1B1 mutation was very less (Table 1) , we did not carry out any further analysis on them.
Haplotype analysis indicated that a 'C-C-G' haplotype in the promoter region was significantly associated with PCG (P ¼ 0.0012). Similarly, this association was stronger among PCG cases that harbored homozygous CYP1B1 mutations (P ¼ 3.42 × 10
212
) and thus it could be a risk haplotype. The 'T-C-G' haplotype was protective (P ¼ 8.11 × 10
). Earlier studies have shown that a risk haplotype in the CYP1B1 coding region 'C-G-G-T-A' harbored the vast majority of mutations across different populations (6, 14) , except Chinese (21) . Based on evolutionary insights and considerations of parsimony, we had demonstrated this to be the ancestral haplotype as majority of the mutations were clustered on this background (14) . We observed strong nonrandom associations of the promoter 'C-C-G' with the 'C-G-G-T-A' risk haplotypes and the protective 'T-C-G' with the 'G-T-C-C-A' coding haplotypes (Fig. 2) . Based on the present study. b Based on our earlier study (19) . Extended haplotype analysis with the T2805C variant and the coding region variants indicated that the C-C-G-G-T-A was the risk haplotype that harbored majority of the CYP1B1 mutations under each phenotype category (Table 4) . Interestingly, this haplotype was strongly associated with PCG cases that harbored homozygous (and compound heterozygous) mutations, but not among single heterozygotes or among those who did not harbor any mutations.
As rs2567206 (T2805C) was the most important SNP in the promoter that influenced the risk in PCG cases with CYP1B1 mutations, we investigated the functional significance of this polymorphism and its effect on the CYP1B1 promoter activity. The choice of the TM3 cell line was based on the pathophysiology of PCG, which is primarily due to raised IOP caused by abnormalities in the drainage structures in the outflow pathway, particularly the trabecular meshwork (2 -4).
The CYP1B1 promoter was active in TM3 cells, with 30-40-fold increase in the luciferase activity in cells transfected with CYP1B1 promoter with the 'T' allele compared with cells transfected with the vector alone. Within each replicate, there was a high reduction in the average luciferase activity (averaged over the two duplicate values within a replicate) in cells transfected with the CYP1B1 promoter with the C allele compared with cells transfected with the T (wild-type) allele. Across the three replicates, relative luciferase activity, averaged over the two duplicate measurements within a replicate, varied from 15 to 47 for the T allele promoter and from 0.7 to 5.0 for the C allele in the promoter. The fold reduction in promoter activity from T to C varied between 9 ( Fig. 3A) and 21.
Genotype-phenotype correlation based on the linear [analysis of variance (ANOVA)] model with fixed and interaction effects showed, as expected, that the effect of coding mutation genotype on presenting IOP was significant (P ¼ 0.022). In addition, also True homozygotes as defined in Table 1 . significant on IOP were (i) the independent effects of genotype at the promoter variant locus (P ¼ 0.001) and (ii) the interaction effect of genotypes at these loci (P ¼ 0.001). These results were similar when the IOP was analyzed separately for each eye. The data on presenting IOP in the patients with respect to their CYP1B1 mutation status and variation at the promoter locus are provided in Supplementary Material, Table S2 . Consistent with these results, the IOP control in PCG patients with CYP1B1 mutations was poorer compared with patients who did not harbor any mutations, as evident from the 1 year post-surgery Kaplan-Meier survival analysis (Fig. 4) .
DISCUSSION
The results of the present study indicated a strong functional association of the rs2567206 SNP in PCG cases harboring homozygous CYP1B1 mutations. This SNP did not exhibit any association in a Chinese cohort with PCG (21) and in a French cohort with POAG (32). This could be attributed to the small sample sizes in both these cohorts as well as the low frequencies of CYP1B1 (homozygous) mutations in them. Screening of the CYP1B1 promoter did not reveal any mutation in the Spanish PCG cohort (33) . No association was observed with rs2567206 in patients with colorectal and prostate cancers (34, 35) . The association of the rs2567206 SNP in our cohort was further supported by haplotype analysis, wherein the presence of the risk allele 'C' in the extended haplotype (C-C-G-G-T-A) was strongly associated with PCG cases with homozygous mutations (Table 4) . Further evidence of strong association of the 'C' allele was determined by mapping the homozygous mutations under different haplotype backgrounds harboring this allele ( Table 5 ). As evident from this table, multiple mutations with varying frequencies were present in the background of the haplotypes harboring the 'C' allele. Also, the 'C' allele did not mark any specific haplotype and was not in LD with any specific mutation.
The T2805C variant led to a significant reduction in the promoter activity of CYP1B1 in cells from the trabecular meshwork. These results suggest that the rs2567206 polymorphism regulates levels of CYP1B1 in vivo and can obviously be involved in the PCG pathogenesis. This is in contrast to an earlier report on rs2567206 in which the investigators did not observe any difference in the promoter activity between the 'T' and 'C' alleles (36) . This discordant finding may be attributed to the use of a different cell line (human bronchial epithelial cell line) used in the study (36) . Analysis of the CYP1B1 promoter using the MatInspector software (http:// www.genomatix.de) and TFsearch (http://www.cbrc.jp/research/db/TFSEARCH. html) suggests that the promoter has putative binding sites for transcription factors such as Nuclear Transcription Factor Y (MIM 189903), Pbx-1 (MIM 176310), GATA-1 (MIM 305371), Nkx-2 (MIM 604612) and Growth FactorIndependent1 [Gfi1 (MIM 600871)], encompassing the rs2567206 polymorphism (Fig. 3B) . It is interesting to note that some of these transcription factors such as Nkx-2, GATA-1 and Pbx-1 regulate patterning during development (37 -39) and could be involved in regulating the development True homozygotes as defined in Table 1. of trabecular meshwork. Whether any of these or other transcription factors/repressors bind and regulate the activity of the CYP1B1 promoter in vivo needs further investigation. Although the underlying molecular mechanism leading to PCG pathogenesis is yet unclear, in vitro studies have hypothesized that CYP1B1 metabolizes an endogenous substrate in order to generate metabolites such as steroids (40), retinoic acid (41) and melatonin (42) that are crucial for development. It has also been suggested that CYP1B1 may completely eliminate a substrate that is required for development (13) . Recently, it has been shown that the coding region mutations in CYP1B1 act either by reducing the enzymatic activity or the abundance of the enzyme or by their combination (43) .
In summary, this study indicated the involvement of the rs2567206 SNP with PCG, but not with POAG or PACG; the association was stronger in PCG patients who harbored a homozygous CYP1B1 mutation. Similarly, the risk haplotype 'C-C-G-G-T-A' exhibited the strongest association among PCG cases harboring homozygous CYP1B1 mutations. Our results indicate that the rs2567206 SNP can be used as an important diagnostic and predictive marker in PCG cases harboring CYP1B1 mutations. Genotype -phenotype correlation indicated, in addition to the significant effect (P ¼ 0.022) of coding mutations, an independent effect of genotype at the promoter (T2805C) locus (P ¼ 0.001), and the interaction effect of genotypes at the promoter and coding region loci (P ¼ 0.001) on the presenting IOP in the worse affected eye. Functional studies further confirmed the regulation of CYP1B1 levels in vivo due to the T2805C variation. 1.51 
MATERIALS AND METHODS

Clinical assessment of the cases
The study protocol adhered to the tenets of the Declaration of Helsinki, and prior approval was obtained from the Institutional Review Board. We examined the promoter region of CYP1B1 in a large cohort of clinically well-characterized subjects (n ¼ 835) that included PCG patients (n ¼ 301) and ethnically and geographically matched unaffected controls (n ¼ 319). We also carried out focused screening of a specific variant in a cohort of primary glaucoma cases that included POAG (n ¼ 115) and PACG (n ¼ 100). The specific clinical diagnosis and enrollment criteria for the patients in each category and the normal controls are provided in refs (14, 19, 22) . The commonality of all the glaucoma cases was the presence of an elevated IOP of .21 mmHg. Peripheral blood samples were collected from all the subjects by venipuncture with prior informed consent. DNA was extracted from blood using standard phenol -chloroform extraction methods as described earlier (14).
Screening of the CYP1B1 promoter
A fully active and functional CYP1B1 promoter has been reported by Wo et al. (44) . Sequence analysis of this region revealed four important regulatory elements, viz. an initiator element, a TATA-like box and two SP1 binding sites (Fig.  1) . In deletion analysis of the promoter, a higher activity of the region containing the TATA-like box and the initiator element was observed, indicating that it is the basal promoter for CYP1B1. Further mutational analysis of these promoter elements indicated that all the four regions were required for a full promoter activity, and deletion of either or both the Sp1 motifs decreased the activity from 80 to 95% (44) . Based on the above data, a 481 bp upstream region (g.2753 -g.3233) that contained all the four regulatory regions was amplified by PCR using a set of forward (5 ′ -AGCGGCCGGGGCAGGTTGTACC-3 ′ ) and reverse (5 ′ -ATTGGGATGGGGACGGAGAA-3 ′ ) primers under standard conditions in a thermal cycler (ABI 9700). PCR amplification was performed in 25 ml of a reaction mixture consisting of 50 ng of genomic DNA, 1× PCR buffer (100 mM of TrisHCl, 500 mM KCl and 0.8% Nonidet P40), 2.5 mM MgCl 2 , 2.5 ml of 2 mM solution of dNTPs, 10% DMSO, 12.5 pmol of each primer and 1 unit of Taq DNA polymerase. An initial denaturation at 948C for 3 min was followed with 30 cycles of amplification (denaturation at 948C for 30 s, annealing at 608C for 30 s and extension at 728C for 45 s) and a final extension at 728C for 7 min. The amplicons were purified using spin-columns (Ultra Clean PCR clean up, MO Bio Laboratories, Loker Ave West, CA, USA) and subjected to resequencing using Big Dye Terminator Chemistry (version 3.1) according to the manufacturer's protocol (Applied Biosystems, Foster City, CA, USA). Both strands were read through an automated ABI 3100 DNA sequencer (Applied Biosystems), and the trace files were analyzed using the Sequencing Analysis Software (version 3.0).
Statistical analysis
Allele frequencies in the patients and controls were calculated by the gene counting method. Test of significance of the difference between allele frequencies was carried out using the chi-square statistic. A P-value of ,0.05 was considered to be statistically significant. Estimates of Hardy -Weinberg equilibrium in the normal controls, reconstruction of haplotypes from genotypes and estimation of haplotyope frequencies were done using Haploview [version 4.0 (45)]. Linkage disequilibria between pairs of loci were estimated using the LD Plot function of this software. Haplotypes were generated with the help of two SNPs in the promoter region (rs2567206 and g.2924C.T), a non-coding SNP (g.3078G.T) and five SNPs in the coding region [rs10012 (R48G), rs1056827 (A119S), rs1056836 (V432L), rs1056837 (D449D) and rs1800440 (N453S)].
Functional analysis of the promoter variant
In order to understand the functional implication of the associated promoter polymorphism (rs2567206), we carried out CYP1B1 promoter assays in the TM3 cell line derived from the trabecular meshwork. The TM3 cells (46) were a gift from Alcon Biosystems, USA. All tissue culture media, supplements and fine chemicals were obtained from Sigma-Aldrich, USA. The cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and antibiotics in humidified incubator at 378C with 5% CO 2 . The region of the CYP1B1 promoter (g.2731 -g.3064), which harbors the basal promoter (44) and an additional upstream promoter sequence, was amplified from genomic DNA of individuals with the homozygous 'TT' and 'CC' genotypes as templates with a set of forward (5 ′ -ACAAGATCTGGCGCGCTCCCAAGTCGAG C-3 ′ ) and reverse (5 ′ -CTAAAGCTTCTCCCACTCCCAC TCCAGAG-3 ′ ) primers using an annealing temperature of 608C and extension of 30 s in a ABI 9700 thermal cycler (Applied Biosystems). A BglII site was introduced in the forward primer and a HindIII site was incorporated in the reverse primer for cloning. The products obtained were cloned into the multiple cloning site of pGL3-Basic vector using BglII and HindIII sites and resequenced for confirmation. Five hundred nanograms of each promoter construct were co-transfected with 1 ng of pRL-TK plasmid expressing Renilla luciferase (Promega), in immortalized trabecular meshwork cell line (TM3) using Fugene HD (Roche) according to the manufacturer's protocol. After 24 h of transfection, cells were lysed in passive lysis buffer and the activities of Firefly and Renilla luciferase were measured using Turner Design Luminometer model TD-20/20 (Promega) according to the manufacturer's instructions.
Each transfection and luciferase-reporting assay was done in duplicate. Therefore, from each assay, we obtained duplicate measurements of the promoter activity for each of the T and C alleles. The experiment was replicated three times.
Genotype -phenotype correlation
We aimed to establish whether the phenotypic effects of the promoter variant were independent of the coding mutations in CYP1B1. In order to address this, we considered presenting IOP of the worse affected eye as a quantitative phenotype and assessed whether the promoter variant and the coding mutations in CYP1B1 have independent and/or interacting effects on IOP. We modeled IOP as the dependent variable, with genotypes at the promoter variant and coding mutations as independent effects and with promoter versus coding variants as an interaction effect, and performed an ANOVA. Additionally, Kaplan -Meier survival analysis was done to understand the prognosis with respect to IOP following a 1 year post-surgical follow-up between PCG cases with and without a CYP1B1 mutation.
